eBook: The new oncology drug development imperatives

Adapting oncology drug development to a post-COVID world.

Oncology is a uniquely complex therapeutic area, and as the coronavirus pandemic has accelerated the adoption of new innovations, such as decentralized clinical trials (DCTs) and real-world evidence (RWE). There will be no going back.

In this new eBook, Parexel experts and one insightful patient explore the many ways COVID-19 has changed drug development — and what new imperatives oncology drug developers can adopt to speed life-changing therapies to patients in need.

• Incorporating novel surrogate endpoints
• Leveraging external / synthetic control arms
• Patient insights for oncology trial design
• Benefits of demonstrating value earlier

Please complete the short form below to download the eBook.

We are always available for a conversation.

Email *
First Name *
Last Name *
Company *
Title *
Phone
Street
City
State/Province*
Country/Area*
Zip
I'm Inquiring About *
Area Of Interest - Multi
Comments *
Submit

We are always available for a conversation.

Submitting...

First Name

Last Name

Title

Company

Email Address

Country

Comments

Communication Preference

Yes, I would like to receive marketing communications including industry insights and trends from Parexel International.

Communication Preference

I would like to receive marketing communications from Parexel and consent to the processing of the personal data that I provide in accordance with and as described in the Privacy Policy.

Accept Decline

Events

Press Releases

Blog

Webinars

Events

Press Releases

Blog

Webinars

eBook: The new oncology drug development imperatives

Adapting oncology drug development to a post-COVID world.

We are always available for a conversation.

Submitting...

Communication Preference

Communication Preference